Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Advanced Non-small-cell Lung Cancer × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 4 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Nasopharyngeal Carcinoma 2 Immunotherapy 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 SCLC, Extensive Stage 1 Mid-low Rectal Cancer 1 Melanoma 1 Locally Advanced Rectal Cancer 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Colonic Neoplasms 1 Advanced Non-small-cell Lung Cancer 1

Interventions

tislelizumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05192681 2022-01-14

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Fujian Cancer Hospital

Phase 2 Unknown

Advanced Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡